Eligibility for Magnetic Resonance Imaging Screening in the United Kingdom: Effect of Strict Selection Criteria and Anonymous DNA Testing on Breast Cancer Incidence in the MARIBS Study

被引:13
作者
Evans, D. Gareth R. [1 ]
Lennard, Fiona [2 ]
Pointon, Linda J. [4 ]
Ramus, Susan J. [3 ]
Gayther, Simon A. [3 ]
Sodha, Nayanta [2 ]
Kwan-Lim, Gek E. [4 ]
Leach, Martin O. [4 ]
Warren, Ruth [6 ]
Thompson, Deborah [5 ]
Easton, Douglas F. [5 ]
Eeles, Rosalind [2 ]
机构
[1] Univ Manchester, St Marys Hosp, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 0JH, Lancs, England
[2] Royal Marsden NHS Fdn Trust, Canc Genet Unit, London, England
[3] UCL, UCL EGA Inst Womens Hlth, Gynaecol Canc Res Lab, London, England
[4] Inst Canc Res, Canc Res UK Clin MR Res Grp, Sutton, Surrey, England
[5] Strangeways Res, Canc Res UK Genet Epidemiol Dept, Cambridge, England
[6] Addenbrookes Hosp, Dept Radiol, Cambridge CB2 2QQ, England
基金
英国医学研究理事会;
关键词
BRCA2 MUTATION CARRIERS; HIGH FAMILIAL RISK; GENETIC RISK; WOMEN; MAMMOGRAPHY; PREDISPOSITION; PENETRANCE; SUSCEPTIBILITY; SURVEILLANCE; MULTICENTER;
D O I
10.1158/1055-9965.EPI-09-0138
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: A UK multicenter study compared the performance of contrast enhanced-magnetic resonance imaging with X-Ray Mammography in women at high-risk of breast cancer commencing in 1997. Selection criteria were used to identify women with at least 0.9% annual risk of breast cancer. Methods: Women at high breast cancer risk, with a strong family history and/or high probability of a BRCA1/BRCA2/TP53 mutation, were recruited from 22 centers. Those not known as gene carriers were asked to give a blood sample, which was tested anonymously for mutations. Women ages 35 to 49 years were offered annual screening for 2 to 7 years. Study eligibility at entry was assessed retrospectively by detailed examination of pedigrees and overall eligibility accounting for computer risk assessment and mutation results. Results: Seventy-eight of 837 (9%) women entered for screening were ineligible using the strict entry criteria. Thirty-nine cancers were detected in 1,869 women-years in study (incidence 21 per 1,000). Including 3,561 further years follow-up, 28 more breast cancers were identified (12 of 1,000). Incidence rates for 759 eligible women were 22 of 1,000 in study and 13 of 1,000 in total follow-up, compared with 9 of 1,000 and 4 of 1,000, respectively, in 78 ineligible women. Breast cancer rates were higher for BRCA2 than BRCA1 after testing anonymized samples in this selected population at 65 of 1,000 in study and 36 of 1,000 in total follow-up for BRCA2 compared with 44 of 1,000 and 27 of 1,000 for BRCA1. Conclusions: Strict enforcement of study criteria would have minimally improved the power of the study, whereas testing for BRCA1/2 in advance would have substantially increased the detection rates. (Cancer Epidemiol Biomarkers Prev 2009;18(7):2123-31)
引用
收藏
页码:2123 / 2131
页数:9
相关论文
共 23 条
  • [1] The BOADICEA model of genetic susceptibility to breast and ovarian cancer
    Antoniou, AC
    Pharoah, PPD
    Smith, P
    Easton, DF
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1580 - 1590
  • [2] Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Antoniou, Antonis C.
    Spurdle, Amanda B.
    Sinilnikova, Olga M.
    Healey, Sue
    Pooley, Karen A.
    Schmutzler, Rita K.
    Versmold, Beatrix
    Engel, Christoph
    Meindl, Alfons
    Arnold, Norbert
    Hofmann, Wera
    Sutter, Christian
    Niederacher, Dieter
    Deissler, Helmut
    Caldes, Trinidad
    Kampjarvi, Kati
    Nevanlinna, Heli
    Simard, Jacques
    Beesley, Jonathan
    Chen, Xiaoqing
    Neuhausen, Susan L.
    Rebbeck, Timothy R.
    Wagner, Theresa
    Lynch, Henry T.
    Isaacs, Claudine
    Weitzel, Jeffrey
    Ganz, Patricia A.
    Daly, Mary B.
    Tomlinson, Gail
    Olopade, Olufunmilayo I.
    Bium, Joanne L.
    Couch, Fergus J.
    Peterlongo, Paolo
    Manoukian, Siranoush
    Barile, Monica
    Radice, Paolo
    Szabo, Csilla I.
    Pereira, Lutecia H. Mateus
    Greene, Mark H.
    Rennert, Gad
    Leibkowicz, Flavio
    Barnett-Griness, Ofra
    Andrulis, Irene L.
    Ozcelik, Hilmi
    Gerdes, Anne-Marie
    Caligo, Maria A.
    Laitman, Yael
    Kaufman, Bella
    Milgrom, Roni
    Friedman, Eitan
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2008, 82 (04) : 937 - 948
  • [3] Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer
    Brown, J
    Coulthard, A
    Dixon, AK
    Dixon, JM
    Easton, DF
    Eeles, RA
    Evans, DGR
    Gilbert, FG
    Hayes, C
    Jenkins, JPR
    Leach, MO
    Moss, SM
    Padhani, AP
    Pointon, LJ
    Ponder, BAJ
    Sloane, JP
    Turnbull, LW
    Walker, LG
    Warren, RML
    Watson, W
    [J]. BREAST, 2000, 9 (02) : 72 - 77
  • [4] Meta-analysis of BRCA1 and BRCA2 penetrance
    Chen, Sining
    Parmigiani, Giovanni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) : 1329 - 1333
  • [5] Guidelines for a genetic risk based approach to advising women with a family history of breast cancer
    Eccles, DM
    Evens, DGR
    Mackay, J
    [J]. JOURNAL OF MEDICAL GENETICS, 2000, 37 (03) : 203 - 209
  • [6] Eeles RA, 1995, CANCER SURV, V25, P101
  • [7] Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting:: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family
    Evans, D. Gareth
    Shenton, Andrew
    Woodward, Emma
    Lalloo, Fiona
    Howell, Anthony
    Maher, Eamonn R.
    [J]. BMC CANCER, 2008, 8 (1)
  • [8] Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
    Ford, D
    Easton, DF
    Stratton, M
    Narod, S
    Goldgar, D
    Devilee, P
    Bishop, DT
    Weber, B
    Lenoir, G
    Chang-Claude, J
    Sobol, H
    Teare, MD
    Struewing, J
    Arason, A
    Scherneck, S
    Peto, J
    Rebbeck, TR
    Tonin, P
    Neuhausen, S
    Barkardottir, R
    Eyfjord, J
    Lynch, H
    Ponder, BAJ
    Gayther, SA
    Birch, JM
    Lindblom, A
    Stoppa-Lyonnet, D
    Bignon, Y
    Borg, A
    Hamann, U
    Haites, N
    Scott, RJ
    Maugard, CM
    Vasen, H
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) : 676 - 689
  • [9] Frebourg T, 2001, B CANCER, V88, P581
  • [10] Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer
    Griebsch, I.
    Brown, J.
    Boggis, C.
    Dixon, A.
    Dixon, M.
    Easton, D.
    Eeles, R.
    Evans, D. G.
    Gilbert, F. J.
    Hawnaur, J.
    Kessar, P.
    Lakhani, S. R.
    Moss, S. M.
    Nerurkar, A.
    Padhani, A. R.
    Pointon, L. J.
    Potterton, J.
    Thompson, D.
    Turnbull, L. W.
    Walker, L. G.
    Warren, R.
    Leach, M. O.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (07) : 801 - 810